22 Nov Enovis Announces Exclusive Agency Agreement with UK Orthopedic Leader Osteotec
Enovis Announces Exclusive Agency Agreement with UK Orthopedic Leader Osteotec. Partnership expands Enovis’ fast-growing business in the UK and Ireland.
GUILDFORD, Surrey, November 22, 2022 – Enovis Corporation, an innovation-driven medical technology company, announced an exclusive partnership with Osteotec, a UK-based orthopedic company focused on extremities, replacement and fixation, to expand the Company’s successful reconstructive business in the UK and Ireland. The appointment of Osteotec as an exclusive Enovis agent is expected to be completed during the remainder of 2022.
The addition of Osteotec adds a strong channel in the UK and Ireland for Enovis’ joint replacement products, including the clinically proven Altivate Reverse® shoulder replacement system, EMPOWRTM products, and extremity solutions. The partnership also strengthens Enovis’ patient-focused innovation pipeline and broadens its reconstructive presence with the complementary addition of many clinically proven surgical solutions from Mathys, an Enovis company, including the Affinis Short shoulder system and unique hip solutions such as the RM – Cup and Optimys hip stem.
“We are very pleased to partner with Osteotec, and even more excited about our ability to quickly advance our orthopaedic leadership in the UK/IRL markets,” said Andrew Jones, Vice President of Business Development of Enovis International. “Osteotec’s differentiated products, deep expertise and talented commercial team will help us accelerate our strategic imperative of delivering superior patient outcomes in this very important market.”
Founded in 1993 and driven by a passion to deliver industry-leading, specialist orthopedic extremities solutions and superior services to healthcare professionals, Osteotec is an established UK/IRL orthopaedics leader headquartered in Newbury, Berkshire, England.
The two businesses look forward to integrating their technology and capabilities for increased efficiencies, improved clinical outcomes and optimized marketing opportunities.
“This exclusive agency agreement builds upon the shared values of both companies, giving our customers more focused support than ever before,” said Anthony McClellan, Osteotec Group General Manager. “We look forward to working with the Enovis team to grow and support sales through our expertise, ensuring our customers receive the highest quality experience and service. Osteotec is dedicated to providing outstanding medical education for our partners, and we are proud to be working with a company that shares our commitment to excellence.”
“Enovis and Osteotec are two leading orthopedic businesses with significant opportunities to work together and distribute the world-leading products while leveraging a deep understanding of this exciting market,” said Andrew Fox-Smith, President, International, of Enovis. “I believe that our UK team, customers and their patients will benefit from this accomplished combination, which will create even greater opportunities for growth and continued success.”
Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.
Enovis Communications Katie.
Osteotec is a UK-based manufacturer and distributor focused on orthopedic extremities. Established in 1993, Osteotec has been supplying into the NHS and private healthcare sectors for the past 29 years. The company’s experienced team of industry experts worked with more than 500 different hospitals across the UK in 2021.